FDA Grants Fast Track Designation to Erasca's ERAS-0015 for Pancreatic Cancer
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca announced FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma, supporting its planned phase 3 and registration-enabling trials.
Key Events · Product Development and Regulatory · ERAS
-
FDA Fast Track Designation Granted
ERAS-0015 received Fast Track Designation for metastatic pancreatic adenocarcinoma, enabling more frequent FDA interactions and potential eligibility for accelerated approval, priority review, and rolling review.
-
Planned Registrational Trials
Erasca plans to initiate a phase 3 clinical trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer for ERAS-0015.
-
Regulatory Milestone for Lead Asset
The designation supports expedited development of ERAS-0015, though it does not change approval standards and the FDA may later revoke the designation.
Analysis · ERAS · Life Sciences
The FDA has granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, a serious condition with high unmet need. This designation enables more frequent FDA interactions and potential eligibility for accelerated approval, priority review, and rolling review. It comes as Erasca plans a phase 3 trial in pancreatic cancer and two potentially registration-enabling trials in lung cancer, positioning the program for expedited development. The designation does not change approval standards, but it is a meaningful regulatory milestone for the company's lead oncology asset.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ERAS was trading at $18.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $1.33 to $24.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.